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Purpose. To report the ability to remove serum dabigatran using continuous renal replacement therapy (CRRT) in a patient with lifethreatening bleeding. Summary. A 77-year-old female with history of atrial fibrillation who takes dabigatran for stroke prevention
presented with abdominal pain. Patient was found to have bleeding and possible mesenteric ischemia and was taken to the operating
room and had continued bleeding postoperatively. CRRT was initiated for the removal of any remaining dabigatran, with serum
dabigatran levels collected to evaluate removal of dabigatran with CRRT. This patient had an increased dabigatran level prior to
intervention, which decreased to an undetectable level after use of CRRT. Greater than 80% of the drug was removed due to 4
hours of CRRT and residual kidney function. Reversal of dabigatran is an area of current research with recent FDA approval of
idarucizumab for use. Conclusion. Bleeding may occur as a result of the use of dabigatran and change in patient’s clinical condition.
Use of CRRT may be an option in removing serum dabigatran in the case of a life-threatening bleed.

1. Introduction
Dabigatran etexilate is an oral reversible direct thrombin
inhibitor, approved for anticoagulation for prevention of
stroke and systemic embolism in nonvalvular atrial fibrillation, as well as the treatment and reduction in risk of
recurrence of pulmonary embolism and deep vein thrombosis (DVT). It offers a predictable anticoagulation response
without the need for routine coagulation test monitoring
and therefore is becoming a viable alternative to vitamin
K antagonists, such as warfarin [1]. The pharmacokinetics
have previously been described in detail [1, 2]. Dabigatran etexilate is rapidly absorbed from the gastrointestinal
tract and quickly hydrolyzed to its active form (dabigatran)
and follows first-order kinetics with a two-compartment
distribution model. Effects of food and drug interactions
are negligible, as the anticoagulant effect is immediate and
predictable. Metabolism occurs by way of liver conjugation
with glucuronic acid, with 80% of unchanged drug recovered
in the urine; therefore, dabigatran must be dose-adjusted for
renal insufficiency. Steady state concentrations are reached

within three days of oral dosing, and the average halflife is 12–17 hours. Although dabigatran exhibits an ideal
pharmacokinetic profile, a potential pitfall to its use is the
difficulty in accurately assessing the degree of anticoagulation
in a supratherapeutic dosing situation [2]. In this report,
we describe a case of utilizing continuous renal replacement
therapy (CRRT) for the removal of dabigatran from the
serum of a patient with an ischemic bowel requiring emergent
surgery. The report of this case did not require Institutional
Review Board review by the investigators institution.

2. Case
A 77-year-old Caucasian female presented to an outside
hospital via Emergency Medical Services with complaints of
abdominal pain, bright red blood in her stools, and an episode
of melena. She was found to be hypotensive and tachycardic
and have coagulation lab abnormalities. The international
normalized ratio (INR) was elevated at 9 and guaiac test
was positive. The patient was given two liters of intravenous
fluids, which stabilized her blood pressure before she was
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transferred to our institution for further evaluation and
treatment.
The patient’s past medical history included paroxysmal
atrial fibrillation, chronic obstructive pulmonary disease, and
depression, with past surgical history of hip repair and left
above-knee amputation. Pertinent oral home medications
included dabigatran etexilate 150 mg twice daily, duloxetine
HCl 30 mg every morning and 60 mg at bedtime, carvedilol
6.25 mg daily, lisinopril 2.5 mg daily, furosemide 40 mg daily,
and diltiazem 120 mg daily. The last known dose of dabigatran
was taken the morning prior to transfer.
Upon admission, the patient was volume-resuscitated
with crystalloid fluids, which improved the blood pressure
and heart rate. Lab abnormalities on presentation to our
facility included hemoglobin and hematocrit (H/H) of 7.2
and 20.6, an increased serum creatinine (SCr) of 1.54 mg/dL
(estimated creatinine clearance of 38 mL/min using Cockcroft Gault (CG) formula [weight 80.6 kg]), activated partial
thromboplastin time (aPTT) of >160 seconds, INR of 6.2,
prothrombin time (PT) of 58.2 seconds, and lactate of
3.5 mmol/L, which decreased to INR of 3.2, prothrombin time
of 31.5 seconds, and lactate of 2.4 mmol/L after 2 units of
packed red blood cells and 3 units of fresh frozen plasma.
Her H/H improved to 9.8 and 27.7, respectively. A physical
examination found the patient to have mild abdominal distention with positive bowel sounds and a left lower quadrant
implanted pain pump.
An additional 2 units of packed red blood cells and 3 units
of fresh frozen plasma were given due to elevated INR, and
the patient was started on a pantoprazole drip for further
management of a gastrointestinal bleed as well as antibiotics for possible infection. A computed tomography scan
of her abdomen/pelvis was obtained which revealed some
thickening of the colon, pneumatosis, and portal venous air,
following which she was seen by general surgery and taken
emergently to the operating room for an exploratory laparotomy. Ischemia of the hepatic flexure was found and resected.
The patient was noted to have a small tear in the liver capsule,
which was sprayed with thrombin and Surgicel, covered with
laparotomy pads and a wound vacuum assisted closure device
was placed. Her labs at this time included H/H of 9.3 and
26.8, INR of 2.8, and aPTT of 80 seconds. Patient had an
estimated blood loss of 2 liters in the operating room and
continued to have oozing from her wound postoperatively. A
nephrology consult was then obtained to initiate dialysis in an
attempt to remove any remaining dabigatran from the serum
that may be contributing to her current bleeding. Access
was obtained, and since the patient remained hypotensive
postoperatively despite volume resuscitation with colloids,
crystalloids, and norepinephrine infusion, the decision was
made to initiate CRRT for treatment of the acute nonoliguric
renal failure as well as to augment dabigatran removal from
the serum. Serum dabigatran levels were determined using
high performance liquid chromatography (HPLC); margin
of error was not reported. Samples were collected prior to
initiation of CRRT, as well as approximately 8, 12, and 24
hours after initiation of CRRT (Figure 1). Serum drug levels
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Figure 1: Serum dabigatran levels and aPTT trend over time.

were send-out tests performed at National Medical Services,
Willow Grove, PA.
CRRT was initiated as continuous venovenous hemodiafiltration (CVVHD/F). The dialysis set utilized the Prismasate system, with the HF1400 polyarylethersulfone filter
(Gambro). CVVHD/F hemofiltration was prescribed at a
total hemofiltration dose of 2500 ml/hr (32 ml/kg/hr) with
a blood flow rate of 250 ml/min, dialysate flow rate of
1500 ml/hr, and replacement flow rate of 1000 mL/hr, with
infused 100% post-filter; the preceding settings are common
rates used at our institution. Circuit anticoagulation was
not initiated as the patient was actively bleeding, requiring
transfusions, and extent of liver injury previously described
was not yet known. A hemofiltration fluid consisting of bicarbonate 22 mEq/L, calcium 0 mEq/L, chloride 120.5 mEq/L,
lactate 3 mEq/L, magnesium 1.5 mEq/L, sodium 140 mEq/L,
and potassium 4 mEq/L was utilized for both dialysate and
replacement.
The initial dabigatran level, collected approximately 2
hours prior to start of CVVHD/F, was 110 ng/mL. This
decreased to 95 ng/mL and 15 ng/mL, 7.5 h (after 5.5 h of
CVVHD/F) and 11.5 h (after 9.5 h of CVVHD/F) after initial level, respectively. The final serum level was obtained
approximately 24 h after the first level and returned undetectable (after 22 h of CVVHD/F). Dialysis was no longer
necessary at this point for the indication of drug toxicity and
rather was continued for volume status and hemodynamic
instability. In relation to the last known time of ingestion
(which was approximately 0900 the morning of transfer),
the levels were drawn at the following intervals: 31.5 h,
39 h, 43 h, and 55 h after the dose. The calculated estimated
creatinine clearance just prior to initiation of CVVHD/F had
improved to 58 mL/min (CG), with adequate urine output
of 1 mL/kg/hour which was maintained throughout the first
48 hours of CRRT therapy, as renal function improved daily
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upon admission. CVVHD/F was continued overnight for
approximately 18 hours until the patient was taken back to
the operating room on hospital day 2 for relaparotomy and
removal of packing and evaluation for ongoing bleeding.
She received another unit of packed red blood cells prior
to operation, with hemoglobin and hematocrit of 7.4 g/dL
and 20.3%, respectively, which was decreased from previous
value, as well as INR of 1.6 and aPTT of 53 seconds at
the time. Hemorrhage was noted to be controlled, blood
and coagulation products were no longer necessary, and
the patient underwent resection of nonviable cecum and
ileostomy creation. The patient returned to the intensive care
unit where CVVHD/F was restarted and continued through
hospital day 4 for management of volume status (3 days
total of CRRT), at which time she returned to the operating
room for removal of packing with fascia and abdominal wall
closure. The patient was transferred to a progressive care unit
and discharged to a nursing and rehabilitation facility on
hospital day 21, a prolonged stay which was not deemed to
be related to bleeding complications. She did return to the
hospital 4 days after discharge for possible infection requiring
an 18-day hospital stay until she was discharged alive.
Pharmacokinetic calculations were done utilizing linear
noncompartmental pharmacokinetic methods [3]. The elimination rate constant (𝑘𝑒 ) was calculated using the only 2
detectable levels which were drawn during the treatment
with CRRT (level 2 = 95 ng/mL and level 3 = 15 ng/mL).
The final level drawn 22 h after CRRT commencement was
not able to be used as it is below the limit of detection
of the laboratory. The 𝑘𝑒 calculation includes elimination
on CRRT plus renal elimination from a calculated GFR of
58 mL/min. Pharmacokinetic parameters are as follows: [𝑘𝑒
= 0.461 hours−1 ] and [elimination half-life = 1.5 hours].
𝐶max and 𝑉𝑑 were not calculated, as the elimination prior to
starting CRRT is not known. Based on calculated clearance,
the dabigatran level would be expected to fall below 1 ng/mL
approximately 6 hours after the last measured serum concentration. Compared to published pharmacokinetic information, the half-life exhibited during the treatment with CRRT
was significantly shorter compared to healthy elderly female
volunteers with normal renal function (1.5 hours versus 13
hours) [2] although our patient did have adequate renal
function during the treatment with CRRT, and this seems
to be a significant decrease in the half-life of this drug. It
is not possible to determine exactly how much clearance is
due to the effects of the CRRT, as effluent levels were not
measured; however, our observed elimination half-life was
approximately 8 times faster than expected [2]. Limitations
to the pharmacokinetic calculations include assumption of
steady state dosing, consistent renal elimination over the
time course of serum sampling, compliance with home
medication regimen, and inability to calculate 𝑉𝑑 . Regardless
of the inherent limitations of the calculations and serum
measurements, we believe that the enhanced clearance seen
with CRRT as well as residual renal function is worth noting.
While it is impossible to predict the exact elimination from
the CRRT circuit without measuring drug effluent levels, the
total dabigatran clearance was observed to be significantly
higher in our patient, as compared to expected clearance
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seen in previous pharmacokinetic studies in a similar patient
population.

3. Discussion
We describe a case of dabigatran induced life-threatening
bleeding, a unique case in which the primary treatment
modality used for reversal was CRRT. Other cases utilizing
CRRT to remove dabigatran from the serum of bleeding
patients have been reported [4, 5], yet data are still lacking
for removal constants and dosage adjustments during CRRT.
Dosing adjustment recommendations exist for patients with
moderate renal dysfunction; however, patients with severe
renal dysfunction were excluded from phase III clinical trials.
A group of patients with end-stage renal disease requiring
intermittent hemodialysis were included in a pharmacokinetic study of dabigatran and it was determined that approximately 68% of the 50 mg dose was removed after the 4-hour
dialysis session, with 62% removed at 2 hours [6]. Chang et
al. describe a case of intermittent hemodialysis for emergent
dabigatran removal which resulted in a serum decrease
in serum dabigatran concentration of about 10 ng/mL per
hour during the time of monitoring. After hemodialysis was
completed, further serum monitoring showed a rebound of
drug levels possibly due to the large volume of distribution
of dabigatran [7]. A well designed pharmacokinetic study
by Khadzhynov et al. reports the results of phase I study of
dabigatran elimination by hemodialysis [8]. Serum levels of
dabigatran were reduced by 59.3% after a four-hour session
of hemodialysis at a blood flow rate of 400 mL/min. At
a lower blood flow rate of 200 mL/min, they observed a
48.8% removal of serum dabigatran. This study is unique in
that the investigators were able to observe greater extent of
extracorporeal removal of dabigatran with a higher blood
flow rate, although the authors state that this effect was not
linear. The investigators of this study did not detect a significant rebound effect of dabigatran after the dialysis session,
although clinically significant bleeding due to rebound drug
levels has been described in a setting of extracorporeal drug
removal [5]. In our case, we did not collect serum dabigatran
levels after the termination of CRRT in order to measure a
rebound effect. The patient required CRRT for 3 days total
to treat the acute nonoliguric renal failure and dabigatran
toxicity; it was assumed at that time that the dabigatran had
been adequately removed from the serum, renal function had
recovered, and the clinically significant bleeding had since
stopped.
Reversal of dabigatran is difficult due to its specific action
on thrombin generation. Vitamin K and protamine will
have little to no effect on reversal [9]. Use of recombinant
factors has been investigated as potential reversal agents,
including recombinant factor VIIa which has been used
to study the reversal effects of direct thrombin inhibitors
with conflicting results [7, 10]. Rat models of bleeding have
shown that activated factor products (PCC), such as FEIBA
(Factor Eight Inhibitor Bypassing Activity), have significantly
slowed bleeding times following dabigatran overdose [11].
In contrast, nonactivated PCCs, such as Cofact, have not
had the same reversal effects on anticoagulation due to
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dabigatran [11]. Additional limitations include the lack of
routinely available four-factor PCCs in the United States
at some institutions due to cost constraints. In an ex vivo
model of dabigatran therapy, Khoo and colleagues examined
the effects of FEIBA on coagulation abnormalities induced
by dabigatran at therapeutic doses (serum concentration
range 96–286 ng/mL). The authors found that a 50 u/kg dose
was efficacious in reversing the effects of dabigatran [12]. A
case presented by Dager et al. reported successful reversal
of a life-threatening bleed caused by dabigatran utilizing
FEIBA [13]. A dose of 26 u/kg actual body weight was used
to treat the bleeding caused by a transseptal perforation
in the presence of anticoagulation with dabigatran. The
aPTT values did not correlate well with clinical bleeding
or doses of FEIBA; however, the bleeding time decreased
in a linear manner after administration of the FEIBA [12,
13]. Idarucizumab, a monoclonal antibody fragment, binds
to both free and thrombin-bound dabigatran to inhibit
its activity and recently gained fast track FDA approval.
The RE-VERSE AD trial showed 100% median maximum
percentage reversal in patients taking dabigatran who had
serious bleeding or required a procedure within 8 hours
[14]. Given the lack of clinical experience of the product,
safety concerns exist. The RE-VERSE AD trial lists several
early and late adverse events of concern including DVT
and ischemic stroke; however, none of these patients were
receiving antithrombotic therapy in a patient population with
known risk (hence taking dabigatran prior to admission).
In addition, cost may be an issue as hospitals predict use
and inventory management. Critical access hospitals should
attempt to carry this product if possible. CRRT may be
considered in a patient who is not able to receive this reversal
agent given drug acquisition due to unavailability or cost
constraints. Additional postmarketing surveillance data will
help determine the role of CRRT in these cases.
Dabigatran was developed as an alternative to warfarin
with less need for routine laboratory monitoring. There are
times when monitoring of the coagulation levels may become
necessary, as in the example above during a life-threatening
bleeding event, although consensus on a readily available
test to define coagulation status in these patients is lacking.
Previous studies have shown that the aPTT is prolonged with
increasing doses of dabigatran, although the result becomes
less accurate with larger doses of the drug [2]. PT and
INR are not significantly altered by therapeutic doses of
dabigatran (although they can be elevated with supratherapeutic concentrations). The ecarin clotting time (ECT) and
thrombin clotting time (TT) have the strongest correlation
with increasing serum drug concentrations, although they are
not widely available as a point-of-care test in most hospitals
[2, 15].

4. Conclusion
The case above reports a successful treatment utilizing CRRT
to remove dabigatran from the serum of a patient with a
life-threatening bleed. The use of CRRT along with residual
kidney function removed 84 percent of the drug serum level
over approximately 4 hours, enhancing the elimination of
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the drug 8-fold compared to healthy volunteers. Although
a 4-hour intermittent hemodialysis session may be a more
efficient modality to dialyze toxic dabigatran levels [5, 8],
our reported case enhances the body of literature suggesting
that CRRT is a safe and efficacious therapy to employ in the
treatment of a dabigatran induced life-threatening bleed in a
hemodynamically unstable patient.
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